Alan DeanJim Traa

Managing Partner

James (Jim) Traa II is a recognized healthcare industry veteran with over 25 years of experience in top-level executive and leadership positions creating markets for innovative technologies. Jim is a General Partner of Targeted Technology Fund I and his experience is in the medical device, life sciences, and personalized medicine arenas with a special emphasis in sales and marketing, operations, product development and introduction, e-commerce, compliance and regulatory affairs, as well as strategic planning, commercialization, and business development.

Previously, Jim was a Vice President for Caris Life Sciences Oncology Division responsible for building the Caris Target Now™ evidence-based tumor profiling business from a start up to market leader. Prior to Caris, Jim held senior leadership positions during 13 years in Genzyme Corporation’s Biosurgical Specialties business unit, where he focused on the development and introduction of novel biotherapeutic and biomaterial products, establishing the Sepra™ brand and Genzyme Biosurgery as the recognized leader in the biomaterials marketplace.



Jim served for nine years as a Commissioned Officer in the United States Navy where he held several leadership positions within the Surface Warfare and Aviation communities. Jim received his BS from the United States Naval Academy and MBA from the University of Texas. He is an active fundraiser and Advisory Board member for The Chromosome 18 Registry and Research Society and a United States Naval Academy Athletic Scholarship Program Trustee.